Increased plasma level of lipoprotein(a) and homocysteine is a marker of increased cardiovascular risk by Đivo Ljubičić et al.







Increased plasma level of lipoprotein(a) and homocysteine is a marker of 
increased cardiovascular risk 
 
Povećana razina lipoproteina(a) u plazmi i homocisteina pokazatelj je povećanog 
kardiovaskularnog rizika 
 




Introduction. Recent molecular research regards Lp(a) as the “third cholesterol” which should be treated 
in the same way like the total and LDL-cholesterol in reduction of total cardiovascular risk. Although early 
data on the relationship between elevated blood homocysteine concentrations and CAD and stroke have been 
somewhat inconsistent, hyperhomocystinemia has been suggested as an indicator of an increased risk of 
cardiovascular disease. In light of this, our study objective was to provide answers to the following questions: 
1. Is serum Lp(a) concentration a risk factor for coronary artery disease in Croatian population; 2. What are 
the frequencies of various apo(a) isoforms in elevated serum Lp(a) concentrations; 3. Is there a relation 
between elevated serum homocysteine and Lp(a) concentration; 4. Investigate the relation of Lp(a) to other 
lipid disorders and other cardiovascular risk factors. 
Methods. This study was performed in Dubrava University Hospital in Zagreb, Croatia. 87 patients 
participated with no known preliminary coronary or peripheral vascular disease. The patient groups were 
stratified according to increased and normal Lp(a) levels measured from serum. Extensive medical history 
was obtained, blood biochemistry was evaluated and all patients underwent exercise stress testing. 
Results. In the group with increased concentration of Lp(a) in serum (> 0.30 g/L) there were 53 patients 
(average age 55 years, 32 males and 21 females), and normal concentration of Lp(a) in serum (< 0.30 g/L) 
was found in 34 patients (average age 52 years, 20 males and 14 females). The patients with increased Lp(a) 
levels were significantly older than the patients with normal Lp(a) levels (p = 0.020). The average 
concentration of Lp(a) in patients with negative exercise stress testing results was 0.38g/L, and in those with 
positive exercise stress testing results it was 0.51 g/L, with this difference among groups being significant (p 
= 0.049). The correlation of homocysteine and Lp(a) levels was statistically significant (r = 0.57, p < 0.01). 
Frequencies of phenotype Lp(a) were determined with the predominance of S4 phenotype (in 34 patients, 
39.10%). 
Conclusions. Lp(a) concentration is a statistically significant risk factor for coronary artery disease. 
Homocysteine and Lp(a) seem to interact to increase the risk of CAD. No significant association was observed 
between Lp(a) levels and conventional risk factors for CAD.  




Uvod. Nedavna molekularna istraživanja smatraju Lp (a) "trećim kolesterolom" koji se treba tretirati na 
isti način kao i ukupni i LDL-kolesterol u smanjenju ukupnog kardiovaskularnog rizika. Iako su rani podaci o 
odnosu između povišenih koncentracija homocisteina u krvi i KBS i moždanog udara bili nekonzistentni, 
hiperhomocistinemija je predložena kao pokazatelj povećanog rizika od kardiovaskularnih bolesti. U tom 
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smislu, cilj našeg istraživanja bio je dati odgovore na sljedeća pitanja: 1. da li je serumska koncentracija Lp 
(a) čimbenik rizika za koronarnu bolest srca u hrvatskoj populaciji; 2. koje su frekvencije različitih apo (a) 
izoformi u povišenim koncentracijama Lp (a) u serumu; 3. postoji li veza između povišene koncentracije 
homocisteina u serumu i koncentracije Lp (a); 4. istražiti odnos Lp (a) prema drugim poremećajima lipida i 
drugim kardiovaskularnim čimbenicima rizika. 
Metode. Istraživanje je provedeno u KB Dubrava u Zagrebu. U istraživanju je sudjelovalo 87 bolesnika 
bez poznatih preliminarnih koronarnih ili perifernih vaskularnih bolesti. Skupine bolesnika stratificirane su 
prema povećanoj i normalnoj razini Lp (a) izmjerene iz seruma. Dobivena je opsežna medicinska povijest, 
napravljena biokemijska analiza krvi i svi bolesnici su podvrgnuti testu opterećenja. 
Rezultati. U skupini s povišenom koncentracijom Lp (a) u serumu (> 0,30 g/L) bilo je 53 bolesnika 
(prosječna dob 55 godina, 32 muškarca i 21 žena), a normalna koncentracija Lp (a) u serumu (< 0,30) g/L) 
nađena je u 34 bolesnika (prosječna dob 52 godine, 20 muškaraca i 14 žena). Bolesnici s povišenim razinama 
Lp (a) bili su značajno stariji od bolesnika s normalnim razinama Lp (a) (p = 0,020). Prosječna koncentracija 
Lp (a) u bolesnika s negativnim rezultatima testa opterećenja bila je 0,38 g/L, a kod osoba s pozitivnim 
rezultatima testa opterećenja 0,51 g / L, pri čemu je ta razlika bila značajna (p = 0,049). Povezanosti razina 
homocisteina i Lp (a) bile su statistički značajne (r = 0,57, p < 0,01). Učestalost fenotipa Lp (a) određena je s 
prevladavajućim fenotipom S4 (u 34 bolesnika, 39,10%). 
Zaključci. Koncentracija Lp (a) statistički je značajan čimbenik rizika za koronarnu bolest srca. Čini se da 
homocistein i Lp (a) djeluju kako bi povećali rizik KBS. Nije uočena značajna povezanost između razina Lp 
(a) i klasičnih čimbenika rizika za KBS. 









Atherosclerosis is responsible for almost all cases 
of coronary artery disease (CAD). This insidious 
process begins with fatty streaks that are first seen in 
adolescence; these lesions progress into plaques in 
early adulthood, and culminate in thrombotic 
occlusions and coronary events in middle age and later 
life. A variety of factors, often synchronous, is 
associated with an increased risk for development of 
atherosclerotic plaques in coronary arteries. The 
conventional risk factors for premature CAD include 
smoking, hyperlipidaemia, hypertension, diabetes and 
a positive family history for CAD. However, many 
patients have precocious atherosclerosis without 
having any of these conventional risk factors. 
Identification of other markers that increase the risk of 
CAD may improve our understanding of the 
pathophysiologic mechanisms of the disorder and 
allow the development of new preventive and 
therapeutic measures. 
Lipid abnormalities play a critical role in the 
development of atherosclerosis. However, the role of 
lipoprotein (a) [Lp(a)] remains controversial. Lp(a) is 
a specialized form of low-density lipoprotein (LDL) 
that is assembled in an extracellular compartment from 
apolipoprotein (a) and LDL.1 Lp(a) can bind to 
macrophages via a high-affinity receptor, possibly 
promoting foam cell formation and localization of 
Lp(a) at atherosclerotic plaques.2 Available literature 
contains somewhat contradictory data on the 
significance and influence of Lp(a) levels on 
cardiovascular risk. Recent molecular research regards 
Lp(a) as the “third cholesterol” which should be treated 
in the same way as total and LDL in reduction of total 
cardiovascular risk.  
Elevated plasma homocysteine level has received 
greater attention in the last few years as an important 
risk factor for vascular disease, including 
atherosclerosis. Although early data on the relationship 
between elevated blood homocysteine concentrations 
and CAD and stroke have been somewhat inconsistent, 
hyperhomocystinemia has been suggested as an 
indicator of an increased risk of cardiovascular 
disease.3,4 The study by Harpel et al. suggested that 
moderate elevations in blood homocysteine could 
significantly increase the affinity of Lp(a) for fibrin 
and perhaps other thrombogenic surfaces and thus be 
an important link in thrombosis and atherogenesis.5 
In light of this, our study objective was to provide 
answers to the following questions: 1. Is serum Lp(a) 
concentration a risk factor for coronary artery disease 
in the Croatian population; 2. What are the frequencies 
of various apo(a) isoforms in elevated serum Lp(a) 
concentrations; 3. Is there a relation between elevated 
serum homocysteine and Lp(a) concentration; 4. What 
is the relation of Lp(a) to other lipid disorders and  
other risk factors; 5. could elevated serum Lp(a) 
concentration be a predictor of atherosclerosis 
progression rate? 
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Extensive medical history was obtained from 
patients presenting at the internal medicine medical 
office on a regular visit due to arterial hypertension, a 
common condition which increases the risk for a 
variety of cardiovascular diseases, aged 50 to 60, of 
both genders and without documented cardiovascular 
disease. Medical history focused on the presence of 
family history of atherosclerotic disease, smoking 
status, nutrition (continental or Mediterranean), 
lifestyle, presence/lack of physical activity and 
possible cardiac or circulatory difficulties. Exclusion 
criteria were documented cardiovascular diseases such 
as coronary artery disease, stroke, heart failure, atrial 
fibrillation and peripheral vascular disease, intake of 
medications that alter the metabolism of lipoproteins, 
such as hypolipemics, oral contraceptives, immuno-
suppressives and beta-blockers.  
Blood biochemistry samples were obtained from 
12-hours fasting precubital vein blood. 
Serum Lp(a) level was assessed in 87 patients 
selected by immunoturbidimetric test that contained 
policlonal Lp(a) antibodies. The cut-off level for 
higher risk for atherosclerosis development was 0.30 
g/L or more. Apo(a) isoform was assessed by sodium-
dodecyl-sulfate (SDS) polyacrylamide gel electro-
phoresis with monoclonal antibodies immunoblotting 
technique. 
Selected patients underwent full physical 
examination, ECG and exercise stress testing by Bruce 
protocol. The presence of positive exercise stress 
testing was used as an indicator of cardiovascular risk 
presence. Brachial arterial blood pressure was assessed 
on both arms by standardized mercury (Hg) 
sphygmomanometer, in supine position after five 
minutes rest. Patients with levels of 140/90 mm Hg and 
higher, and those taking antihypertensives were 
considered as hypertensive. The body mass index 
(BMI) was calculated as a ratio of body mass in 
kilograms and second power of body height in meters. 
The normal range was considered as from 18.5 to 24.9. 
Triglycerides level was assessed by the photometric 
method with normal ranges for men and women < 1.7 
mmol/L. Cholesterol was assessed by the CHOD-PAP 
method. Normal values were considered as < 4.5 
mmol/L. High-density lipoprotein (HDL) was assessed 
by same method after detergent extraction of LDL and 
very-low-density lipoprotein (VLDL), with reference 
values for men and women > 1.0 mmol/L and > 1.2 
mmol/L respectively. LDL was assessed directly from 
serum with Tr-53101 reagens, with reference values 
for men and women < 2.5 mmol/L. Apo (a-1) and Apo 
(b) were assessed by the immunoturbidimetric method. 
Reference values for Apo (a-1) were for 0.73 to 1.69 
g/L, and for Apo (b) from 0.58 to 1.38 g/L. 
Homocysteine serum concentration was assessed by 
fluorescence polarization immunoassay. Normal value 
was considered lower than 12 μmol/L. Fibrinogen was 
assessed quantitatively by the modified BEHRING 
method. Normal values were from 1.8 to 3.5 g/L. 
Statistical analysis was preformed on a computer 
with statistical software SPSS (Statistical Package for 
social science, SPSS for Windows 7.5, SPSS Inc. 
Chicago, USA). Distribution of serum lipoprotein (a) 
and homocysteine concentrations were described as 
median and interval numeric data, and nominal data 
was described with frequency. 
Numeric data was compared with the Mann-
Whitney test and Pearson correlation coefficient. 
Distributions of nominal values were compared with χ2 
and proportion tests. In all performed tests, the 
observed significance level was p < 0.05 and 




In total, 87 patients were included in the study, of 
which 53 had Lp(a) > 0.30 g/L, and 34 had Lp(a) < 
0.30 g/L. There was no significant difference among 
those two groups in regards to age, gender, body 
height, body mass, presence of positive family history 
for CAD, smoking, hypertension and nutrition. 
When comparing patients with Lp(a) concentration 
higher than 0.30 g/L and those with Lp(a) 
concentration lower than 0.30 g/L, the first group had 
significantly higher levels of homocysteine in serum, 
as showed in Table 1. The correlation of homocysteine 
and Lp(a) levels was significant (r = 0.57, p < 0.01). 
Lp(a) phenotype frequencies were determined 
(Table 2), with clear predominance of S4 phenotype 
(in 34 patients, 39.10%). Its frequency in subjects with 
negative exercise stress testing was up to 50.00%, and 
was significantly higher than in those with positive 
exercise stress testing (21.20%). No significant 
differences were found in frequencies of other 
phenotypes (S1, S1S2, S2, S2S3, S2S4, S3, S3S4, S4 
and S5) when comparing groups by results of exercise 
stress testing. 
The group with low molecular mass apo(a) 
phenotype (S0, S1, S2, S1S2, S2S3, S2S4) had 
significantly higher homocysteine levels than the group 
with high apo(a) molecular mass phenotype (S3, S4, 
S3S4), 13.15 (6.3 – 32.7) μmol/L and 11.2 (5.4 – 18.4) 
μmol/L, respectively, with this difference between 
groups being significant (p = 0.026). The tendency for 
higher Lp(a) levels in group with phenotype apo(a) of 
low molecular mass was observed (Table 3).
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Table 1 Average values and standard deviations of lipids, fibrinogen, homocysteine and glucose in blood serum 
in all patients, in groups with normal and elevated Lp(a) levels 
Tablica 1. Prosječne vrijednosti i standardna odstupanja lipida, fibrinogena, homocisteina i glukoze u krvnom 
serumu kod svih bolesnika, u skupinama s normalnom i povišenom razinom Lp (a) 
 
 All patients  
(N = 87) 
Svi pacijenti 
Lp(a) < 0.30 g/L  
(N = 34) 
Lp(a) > 0.30 g/L  




1.89 (0.40 – 8.50) 2.01 (0.58 – 7.03) 1.64 (0.40 – 8.50) -1.55 0.120 
Cholesterol 
(mmol/L) 
5.40 (0.40 – 8.50) 5.27 (3.70 – 7.30) 5.49 (2.20 – 10.35) -0.6 0.548 
HDL (mmol/L) 0.93 (0.27 – 1.81) 0.92 (0.42 – 1.81) 0.96 (0.27 – 1.64) -0.45 0.651 
LDL (mmol/L) 3.45 (0.54 – 7.86) 3.38 (0.72 – 7.86) 3.57 (0.54 – 5.38) -0.02 0.983 
Fibrinogen (g/L) 3.00 (1.10 – 5.30) 2.80 (1.10 – 5.20) 3.00 (1.14 – 5.30) -0.84 0.398 
Homocysteine 
(umol/L) 
11.55 (5.40 – 32.70) 9.55 (5.40 – 16.90) 12.85 (6.30 – 32.70) -3.87 <0.001 
Blood glucose 
(mmol/L) 
Glukoza u krvi 
5.20 (4.00 – 12.90) 4.95 (4.10 – 10.90) 5.40 (4.00 – 12.90) -0.65 0.101 
 
 
Table 2 Lp(a) phenotype frequencies and their relation to exercise stress testing result 
Tablica 2. Frekvencije fenotipa (a) i njihova veza s rezultatom ispitivanja testiranja otpornosti na stres 
 
Phenotype All patients (N = 87) 
Svi pacijenti 
Positive EST* (N = 33) Negative ESTR* (N = 54) χ2 P 
S1 4 (4.6%) 2 (6.15%) 2 (3.7%) 0.01 0.993 
S1S2 5 (5.7%) 2(6.1%) 3 (5.6%) 0.14 0.708 
S2 9 (10.3%) 3 (9.1%) 6 (11.1%) 0.01 0.945 
S2S3 6 (6.9%) 5 (15.2%) 1 (1.9%) 3.73 0.055 
S2S4 3 (3.4%) 3 (9.1%) 0 2.75 0.099 
S3 11 (12.6%) 5 (15.2%) 6 (11.1%) 0.05 0.827 
S3S4 9 (10.3%) 4 (12.1%) 5 (9.3%) 0.01 0.959 
S4 34 (39.1%) 7 (21.2%) 27 (50.0%) 5.97 0.016 
S0 6 (6.9%) 2 (6.1%) 4 (7.4%) 0.04 0.847 
* exercise stress testing result 
* vježbe testiranja otpornosti na stres 
 
 
Table 3 Average values of Lp (a) in regards to apo (a) phenotype 
Tablica 3. Prosječne vrijednosti Lp(a) u odnosu na apo (a) fenotip 
 
 S1  
(N = 4) 
S1S2  
(N = 5) 
S2  
(N = 9) 
S2S3 
(N = 6) 
S2S4 
(N = 3) 
S3  
(N = 11) 
S3S4 
(N = 9) 
S4  
(N = 34) 
S0  
(N = 6) 
Lp(a) 
(mmol/L) 
0.12 0.99 0.77 0.68 0.58 0.55 0.43 0.31 0.26 
 
In the group with positive exercise stress 
testing result fasting blood glucose and Lp(a) levels 
were significantly higher than in the group with 
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Table 4 Concentration of Lp(a) and fasting blood glucose in regards to exercise stress testing results 
Tablica 4. Koncentracija Lp (a) i glukoze u krvi nakon posta u odnosu na rezultate vježbe testiranja otpornosti 
na stres 
 Negative ESTR* (N = 54) Positive ESTR* (N = 33) χ2 P 
Lp(a) (g/L) 0.38 (0.21 – 1.40) 0.51 (0.23 – 1.40) -1.86 0.049 
Glucose (mmol/L) 5.20 (4.0 – 10.9) 5.9 (4.30 – 12.90) -2.57 0.012 
* exercise stress testing result 




Many clinical studies of CAD, cerebrovascular 
disease and peripheral artery disease have been 
undertaken to assess the association of Lp(a) with 
disease.6,7,8 In this cross-sectional study designed to 
determine the association of Lp(a) and CAD, it was 
found that serum Lp(a) concentration is a statistically 
important risk factor for coronary artery disease in the 
Croatian population. These results are consistent with 
the data from literature on Lp(a) as a risk factor for 
atherosclerosis, but are unique in the aspect of relating 
elevated levels of Lp(a) with positive stress exercise 
testing as a marker of CAD in asymptomatic 
individuals. The study by Uterman et al. showed that 
Lp(a) phenotypes S1 and S2 are associated with high 
and phenotypes S3 and S4 with low Lp(a) 
concentrations.9 In this study we noticed the tendency 
for higher Lp(a) levels in the group with phenotype 
apo(a) of low molecular mass. The simplest 
explanation for this ought to be that the same genes are 
involved in determining both electrophoretic Lp(a) 
phenotypes and Lp(a) lipoprotein concentrations in 
plasma. Our group noted the predominance of S4 
phenotype (in 34 patients, 39.10%) and its frequency 
in subjects with negative exercise stress testing that 
was up to 50.00%, and was significantly higher that in 
those with positive exercise stress testing (21.20%). 
A high homocysteine level may act in concert with 
a high Lp(a) level to promote atherosclerosis and or 
vascular disease. The existence of this link was also 
described in several other studies. Harpel et al5 initially 
suggested that homocysteine promoted the binding of 
Lp(a) to plasmin-modified fibrin. This could 
potentially lead to more atherogenesis and 
atherothrombosis associated with elevations of both 
homocysteine and Lp(a). It is now known that Lp(a) is 
composed of apo(a) linked to an apolipoproteine(B)-
100-LDL [apo(B)-100–LDL] particle by a single 
disulfide bond. Thiols, such as homocysteine, are 
known to dissociate apo(a) from the Lp(a) complex, 
leading to the exposure of an additional lysine-binding 
site on apo(a). This additional lysine-binding site may 
increase the affinity of apo(a) for plasmin-modified 
fibrin, thus impeding fibrinolysis.10 Our findings 
support the hypothesis that homocysteine and Lp(a) 
interact to increase the risk of CAD. 
The link between Lp(a) concentration and well 
established risk factors for premature CAD (smoking, 
hyperlipidaemia, hypertension, diabetes and presence 
of positive family history for CAD) has been 
evaluated. No significant association trend was 
observed between obesity and Lp(a) levels. In spite of 
the various hypotheses that the smoking habit may 
exert on the lipid metabolism, there was no positive 
association between tobacco use and Lp(a) levels 
neither in this study nor in other studies.11 Considering 
that the selection of patients was very carefully 
performed to avoid other influences on Lp(a) 
concentrations inconsistent with the presence of the 
smoking habit, studies of a larger number of very 
carefully selected cases are required. With respect to 
blood pressure, it has not been demonstrated that there 
is any association between the systolic or diastolic 
component of arterial blood pressure and Lp(a) levels. 
Those observations have been confirmed by a study 
examining hypertensive and non hypertensive 
individuals which also did not observe differences in 
the concentration of Lp(a). The study by Cândido et al. 
found that Lp(a) levels were significantly associated 
with the presence of ischemic heart disease.12 In 
relation to other cardiovascular risk factors, it was 
verified that Lp(a) levels were statistically associated 
with age, total cholesterol, LDL-cholesterol and 
percentage of body fat determined by bioelectric 
impedance, but not arterial hypertension. In contrast, 
Catalano et al. reported significantly elevated levels of 
plasma Lp (a) in 123 Caucasian essential arterial 
hypertensive patients (47 men and 76 women).13 
Although our study confirmed a significant relation 
between fasting blood glucose level and exercise stress 
testing results, no correlation was demonstrated when 
comparing serum glucose level in the group with high 
Lp(a) level and normal Lp(a) level. This could be 
explained by our hypothesis that Lp(a) is an 
independent risk factor for CAD. Answers whether 
relation exists are still contradictory. The study by 
Khare et al. showed that Lp(a) levels were elevated in 
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diabetes, especially type 2, when compared with the 
non-diabetic subjects or type 1.14 Other studies 
confirmed that impaired glucose tolerance was not 
related with Lp(a) levels.12  
This study hasn’t found a correlation between Lp(a) 
concentrations and the presence of dyslipidemia, 
which may suggest that Lp(a) level is not influenced 
by other dyslipidemic conditions. Contrary to this 
study, a similar study performed by Boyer et al. 
observed a significant difference between the median 
Lp(a) level of the normolipidemic group and of the 
dyslipidemic group as a whole. Median Lp(a) levels in 
the 4 dyslipidemic groups did not differ significantly.15 
Another study by Bartens et al. indicates that plasma 
Lp(a) concentrations are elevated in hyperlipidaemia if 
patients have high cholesterol levels, whereas Lp(a) is 
normal to low in patients with elevated triglycerides.16 
Further analysis of this contradictory data is necessary 
in a larger prospective study.  
Although this study confirmed that serum Lp(a) 
concentration is a risk factor for coronary artery 
disease in the Croatian population, our hypothesis that 
elevated serum Lp(a) concentration could be a 
predictor of atherosclerosis progression rate couldn’t 
have been tested in this cross – sectional study due to 
limitations of this study design. The study by 
Hartmann et al. suggested an increasing significance of 
Lp(a) in predicting cardiovascular risk.17 A large 
randomized prospective study is required to address 
this question and to determine the existence of positive 





This study confirmed that serum Lp(a) 
concentration is a statistically significant risk factor for 
coronary artery disease in the Croatian population. No 
significant association was observed between Lp(a) 
levels and conventional risk factors for CAD. This 
finding is important because it shows that elevated 
lipoprotein Lp(a) is associated with CAD and it adds 
to the poll of evidence that Lp(a) should be treated in 
the same way as total and LDL in reduction of total 
cardiovascular risk. A high tendency exists for higher 
Lp(a) levels in the group with phenotype apo(a) of low 
molecular mass, which is indicative that size, as well 
as amount, is important - that the smaller the Lp(a) 
particle, the higher the risk of heart disease. 
Our findings support the hypothesis that homo-
cysteine and Lp(a) interact to increase the risk of CAD 
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